Prosecution Insights
Last updated: April 19, 2026
Application No. 18/558,166

PROCESS FOR THE PREPARATION OF ANTIBACTERIAL COMPOUNDS

Non-Final OA §112
Filed
Oct 30, 2023
Examiner
LEESER, ERICH A
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Discuva Limited
OA Round
1 (Non-Final)
82%
Grant Probability
Favorable
1-2
OA Rounds
2y 3m
To Grant
95%
With Interview

Examiner Intelligence

Grants 82% — above average
82%
Career Allow Rate
773 granted / 948 resolved
+21.5% vs TC avg
Moderate +14% lift
Without
With
+13.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
15 currently pending
Career history
963
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
12.7%
-27.3% vs TC avg
§102
22.0%
-18.0% vs TC avg
§112
38.4%
-1.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 948 resolved cases

Office Action

§112
DETAILED ACTION This action is in response to Applicant’s submission dated April 12, 2024, in which Applicant amended claims 3-4, 14-15, 18, 20-21, 23-24, 29, 31, 33-34, 37, 41, and 43-45, and canceled claims 5-13, 16-17, 19, 22, 25-26, 28, 30, 32, 35, 38-40, and 46-49. Information Disclosure Statement The references contained in the IDS dated February 6, 2026 and October 30, 2023 are made of record. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Specification The Specification is objected to because a Brief Description of the Drawings section is lacking for Figures 1a, 1b, 1c, 1d, 2, 3, 4a, 4b, 4c, 5, 6a, 6b, and 6c. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claims 2, 3, 20-21, 24, 29, and 33 are rejected under 35 U.S.C. 112(b) and/or (d),. Claim 2 is rejected under 35 U.S.C. 112(d) because it is of the same scope and therefore redundant of claim 1. Examiner recommends cancelation of claim 2. Parent claim 3 is rejected under 35 U.S.C. 112(b) because it recites “and/or” in step (a) for compounds 10 and 10A and dependent claim 4 recites “and”, so the scope of claim 4 is narrower than parent claim 3. A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) is considered indefinite, since the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). Note, for example, the decisions of Ex parte Steigewald, 131 USPQ 74 (Bd. App. 1961); Ex parte Hall, 83 USPQ 38 (Bd. App. 1948); and Ex parte Hasche, 86 USPQ 481 (Bd. App. 1949). In the present instance, claim 20 is rejected under 35 U.S.C. 112(b) because it recites the broad recitation salt of (10) and/or a salt of (10A), and the claim also recites preferably a hydrochloride salt of (10) and/or a hydrochloride salt of (10A), which is the narrower statement of the range/limitation. Further, it recites preferably the dihydrochloride salt (10C) and/or the dihydrochloride salt (10D). Correction is required. Similarly, claim 21 is rejected under 35 U.S.C. 112(b) because it recites broader base and preferably a tertiary amine, which is narrower and also more preferably pyridine, which is the narrowest. Correction is required. Further, claim 24 is rejected under 35 U.S.C. 112(b) because it recites the broader NaOH, then preferably 30% aq. NaOH solution, which is narrower. Correction is required. Claim 29(b) is rejected under 35 U.S.C. 112(b) because the 1 is missing from the beginning of (7). Correction is required. Finally, claim 33 is rejected under 35 U.S.C. 112(b) because it recites metal catalyst, followed by preferably the metal catalyst is palladium (II) acetate, which is narrower. Regarding element (b) of claim 33 is rejected under 35 U.S.C. 112(b) because the phrase "such as" renders the claim indefinite because it is unclear whether the limitations following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Claim Objections Claims 4 and 34 are objected to as being dependent upon rejected dependent claims 3 and 33, respectively, but would be allowable if rewritten in independent form including all of the limitations of the base claims and any intervening claims. Conclusion Any inquiry concerning this communication or earlier communications from the Examiner should be directed to ERICH A LEESER whose telephone number is (571) 272-9932. The Examiner can normally be reached Monday through Friday from 10-6 PST, M-F. PST. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner’s supervisor, Mr. James Alstrum-Acevedo can be reached at (571) 272-5548. The fax number for the organization where this application is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) toll-free at 866-217-9197. If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ERICH A LEESER/Primary Examiner, Art Unit 1622 United States Patent and Trademark Office Tel. No.: (571) 272-9932
Read full office action

Prosecution Timeline

Oct 30, 2023
Application Filed
Jan 26, 2026
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12590082
FUSED TRICYCLIC DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF
2y 5m to grant Granted Mar 31, 2026
Patent 12589099
ALPHA-1062 FOR TREATING TRAUMATIC BRAIN INJURY
2y 5m to grant Granted Mar 31, 2026
Patent 12590106
SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS
2y 5m to grant Granted Mar 31, 2026
Patent 12570622
THERAPEUTIC COMPOUNDS
2y 5m to grant Granted Mar 10, 2026
Patent 12565518
HYBRID CYCLIC LIBRARIES AND SCREENS THEREOF
2y 5m to grant Granted Mar 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
82%
Grant Probability
95%
With Interview (+13.5%)
2y 3m
Median Time to Grant
Low
PTA Risk
Based on 948 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month